We are a translational Immune-Oncology research lab that studies novel approaches in sensitizing hard-to-treat cancers to immunotherapy. Our research involves understanding the interactions between the immune cells and cancer and learning the effect of novel treatments in cancer patients via phase I clinical trials. We work closely with cancer patients and clinicians, including medical oncologists, radiation oncologists, surgeons, and infectious disease specialists.
T-cells are the main focus of our research, and we are trying to understand how the anti-tumor function of these cells can be improved in different cancers. As a tumor-agnostic lab, we focus on the immune system, which allows us to learn and apply immune-stimulatory mechanisms in various cancers. Currently, we have Immuno-Oncology projects in melanoma, renal cell carcinoma, pancreatic cancer, breast cancer, prostate cancer, lung cancer, head and neck cancer, and neuroblastoma (a form of childhood cancer).
A major drawback in medical research is the lack of close collaboration between Ph.D. scientists and clinicians. Our lab is based on an integrated model that allows Ph.D. scientists to spend time in the clinic with clinicians and medical fellows and clinicians to spend time working with scientists.
Also, we believe that science should be fun and helpful to humanity and patients. Therefore, we always try to learn from each other, help each other achieve our goals, and ultimately help cancer patients.
A world without cancer is a better world, and we are working together to eradicate cancer.
CONTACT US
London Regional Cancer Program
Room A4-130A
Cancer Research Laboratory Program
790 Commissioners Rd. E.
London, Ontario
Canada N6A 4L6
t. 1.519.685.8500 ext. 55769
e. saman.malekivareki@lhsc.on.ca